Advertisement
"We are pleased that Wyeth has extended the research period of ourcollaboration," said Peter Thompson, M.D., FACP, president, CEO and chairmanof Trubion. "Wyeth's ongoing commitment to the collaboration underscores thepotential of our technology, and we look forward to continuing our effortswith Wyeth as we pursue the development of additional first-in-class andbest-in-class compounds."
Advertisement
In December 2005, Trubion entered into a collaboration agreement withWyeth for the development and worldwide commercialization of TRU-015 and otherCD20-directed therapeutics. The agreement also includes the development andworldwide commercialization of certain other product candidates directed to asmall number of targets other than CD20 that have been established pursuant tothe agreement. Unless earlier terminated, the agreement will remain in effecton a product-by-product basis and on a country-by-country basis until thelater of the date that any such product shall no longer be covered by a validclaim of a U.S. or foreign patent or application and, generally, 10 yearsafter the first commercial sale of any product licensed under the agreement.Wyeth may terminate the agreement without cause at any time upon 90 days'prior written notice.
Trubion retains the right to develop and commercialize, on its own or withothers, product candidates directed to all targets not included within theagreement, including CD37.
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline ofnovel protein therapeutic product candidates to treat autoimmune andinflammatory diseases and cancer. The company's mission is to develop avariety of first-in-class and best-in-class product candidates, customized foroptimal safety, efficacy, and convenience that it believes may offer improvedpatient experiences. Trubion's current product candidates are novelsingle-chain protein, or SMIP(TM), therapeutics, and are designed using itscustom drug assembly technology. Trubion's product pipeline includesCD20-directed candidates such as TRU-015 and SBI-087 for autoimmune andinflammatory diseases, developed under the company's Wyeth collaboration.Trubion's product pipeline also includes Trubion's proprietary productcandidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cellmalignancies that is currently in Phase 1/2 clinical evaluation. In additionto Trubion's current product candidates, the company is also developingadditional alliance and proprietary product candidates that build on itsproduct development experience. More information is available in the investorssection of Trubion's website: investors.trubion.com.
Forward-Looking Statements
Certain statements in this release may constitute "forward-lookingstatements" within the meaning of Section 21E of the Securities Exchange Actof 1934 and Section 27A of the Securities Act of 1933. These statementsinclude, but are not limited to, those related to the potential developmentand commercialization of new products under the Wyeth collaboration agreement.These statements are based on current expectations and assumptions regardingfuture events and business performance and involve certain risks anduncertainties that could cause actual results to differ materially. Theserisks include, but are not limited to, risks associated with the company'sWyeth collaboration, i
